HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases

Genes Chromosomes and Cancer

Volumn 56, Issue 8, 2017, Pages 598-607

  Sun, Huizhi ^a   Liu, Tieju ^a   Zhu, Dongwang ^a   Dong, Xueyi ^a   Liu, Fang ^a   Liang, Xiaohui ^a   Chen, Chen ^a   Shao, Bing ^a   Wang, Meili ^a   Wang, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD44V ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; ALDEHYDE DEHYDROGENASE; HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN GROUP M; HNRNPM PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

AGGRESSIVENESS; ALTERNATIVE RNA SPLICING; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL INVASION ASSAY; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; EXON; GEL ELECTROPHORESIS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LENTIVIRINAE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; BREAST TUMOR; CELL MOTION; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; SURVIVAL ANALYSIS;

ALDEHYDE DEHYDROGENASE; ANTIGENS, CD44; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL MOVEMENT; FEMALE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP M; HUMANS; LYMPHATIC METASTASIS; MCF-7 CELLS; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 85018390204     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22463     Document Type: Article

References (34)

1. Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135:851–867.
2. Chaudhury A, Chander P, Howe PH. Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles. RNA 2010;16:1449–1462.
3. Eder S, Arndt A, Lamkowski A, et al. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K). Cancer Lett. 2017;385:160–167.
4. Lai CH, Huang YC, Lee JC, et al. Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer. Cell Death Dis. 2017;8:e2555.
5. Zhou X, Li Q, He J, et al. HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis. Oncotarget 2016.
6. Chen S, Zhang J, Duan L, et al. Identification of HnRNP M as a novel biomarker for colorectal carcinoma by quantitative proteomics. Am J Physiol Gastrointest Liver Physiol. 2014;306:G394–G403.
7. Lleres D, Denegri M, Biggiogera M, Ajuh P, Lamond AI. Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice. EMBO Rep. 2010;11:445–451.
8. Cho S, Moon H, Loh TJ, et al. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7. Biochim Biophys Acta. 2014;1839:306–315.
9. Dery KJ, Gaur S, Gencheva M, Yen Y, Shively JE, Gaur RK. Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M. J Biol Chem. 2011;286:16039–16051.
10. Park E, Iaccarino C, Lee J, et al. Regulatory roles of heterogeneous nuclear ribonucleoprotein M and Nova-1 protein in alternative splicing of dopamine D2 receptor pre-mRNA. J Biol Chem. 2011;286:25301–25308.
11. Xu H, Wu K, Tian Y, et al. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol. 2016;49:1343–1350.
12. Sacks JD, Barbolina MV. Expression and Function of CD44 in Epithelial Ovarian Carcinoma. Biomolecules. 2015;5:3051–3066.
13. Birzele F, Voss E, Nopora A, et al. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clin Cancer Res. 2015;21:2753–2762.
14. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med. (Maywood) 2013;238:324–338.
15. Olsson E, Honeth G, Bendahl PO, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 2011;11:418.
16. Schmitt M, Metzger M, Gradl D, Davidson G, Orian-Rousseau V. CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ 2015;22:677–689.
17. Afify AM, Tate S, Durbin-Johnson B, Rocke DM, Konia T. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers. 2011;26:50–57.
18. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121:1064–1074.
19. Friedrichs K, Franke F, Lisboa BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 1995;55:5424–5433.
20. Loh TJ, Moon H, Cho S, et al. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. Oncol Rep. 2015;34:1231–1238.
21. Zhou ZJ, Dai Z, Zhou SL, et al. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer. 2013;132:1080–1089.
22. Loh TJ, Cho S, Moon H, et al. hnRNP L inhibits CD44 V10 exon splicing through interacting with its upstream intron. Biochim Biophys Acta. 2015;1849:743–750.
23. Liu T, Sun B, Zhao X, et al. OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer. Int J Mol Sci. 2014;15:19634–19649.
24. Liu T, Sun B, Zhao X, et al. USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry. Mol Cancer Ther. 2015;14:2121–2131.
25. Liu T, Niu Y, Yu Y, Liu Y, Zhang F. Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol. 2009;20:441–448.
26. Meng J, Sun B, Zhao X, et al. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma. Mol Cancer Ther. 2014;13:3107–3122.
27. Xu Y, Gao XD, Lee JH, et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev. 2014;28:1191–1203.
28. Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients. Diagn Pathol. 2014;9:79.
29. Zhong Y, Lin Y, Shen S, et al. Expression of ALDH1 in breast invasive ductal carcinoma: An independent predictor of early tumor relapse. Cancer Cell Int. 2013;13:60.
30. Thomas P, Forse RA, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis. 2011;28:923–932.
31. Mladinich M, Ruan D, Chan CH. Tackling Cancer Stem Cells via Inhibition of EMT Transcription Factors. Stem Cells Int. 2016;2016:5285892.
32. Pradella D, Naro C, Sette C, Ghigna C. EMT and stemness: Flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16:8.
33. Wang LL, Hao S, Zhang S, et al. PTEN/PI3K/AKT protein expression is related to clinicopathologic features and prognosis in breast cancer with axillary lymph node metastases. Hum Pathol. 2017;61:49–57.
34. Ahmed AR. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer. J Egypt Natl Canc Inst. 2016;28:219–227.